Key Takeaways & Executive Findings
- ā¢ā¢ Integrates three key domains: scaffold-guided stem cell strategies, tooth organoids, and molecular targeted therapies for tooth regeneration. ⢠Highlights the use of dental stem cells (DPSCs, SCAPs, PDLSCs, SHED) and iPSC-derived lineages with bioactive scaffolds to promote odontogenic differentiation and periodontal attachment. ⢠Emphasizes the role of tooth organoids in recapitulating epithelial-mesenchymal interactions and modeling human odontogenesis. ⢠Discusses molecular pathways (Wnt, BMP, FGF, TGF-β, USAG-1) as therapeutic targets for endogenous regeneration, while acknowledging challenges in neurovascular integration and long-term stability.
Abstract
Tooth loss remains a major unmet clinical challenge, and current prosthetic approaches cannot restore the biological complexity, sensory function, or regenerative capacity of natural teeth. Recent progress in stem cell biology, developmental engineering, and regenerative biomaterials has opened new possibilities for biological tooth regeneration. This review integrates advances across three major research domains that together define the current landscape of translational regenerative dentistry. First, we discuss stem cell-based, scaffold-guided strategies for tooth regeneration. These approaches combine dental and nondental stem cells, including DPSCs, SCAPs, PDLSCs, SHED, and iPSC-derived lineages, with bioactive materials such as HA/TCP ceramics, dentin-derived extracellular matrix scaffolds, and natural or synthetic polymers to promote odontogenic differentiation, vascularization, and periodontal attachment. Second, we summarize emerging tooth organoid and bioengineered tooth germ technologies that recapitulate epithelialāmesenchymal interactions and enable controlled reconstruction of dentināpulp and periodontal compartments for modeling human odontogenesis. Third, we highlight molecular regulation-driven therapeutic strategies, focusing on the modulation of Wnt, BMP, FGF, TGF-β, and USAG-1 pathways to stimulate endogenous tooth regeneration and correct developmental defects. Despite marked progress, challenges remain, including stable neurovascular integration, optimization of stem cellāmaterial crosstalk, precise control of spatiotemporal signaling, and long-term functional stability in vivo. Finally, we outline future directions involving smart biomaterials, gene- and protein-based molecular targeting, organoid-guided regeneration, and iPSC-enabled personalized therapies, which may further accelerate the clinical translation of stem cell-based tooth regeneration.
1. Introduction
Tooth development in humans is a highly orchestrated process involving sequential epithelialāmesenchymal interactions, tightly regulated molecular signaling pathways (e.g., BMP, FGF, and Wnt), and coordinated cellular differentiation events. During embryogenesis, the initiation of the dental lamina gives rise to the tooth germ, which progresses through the bud, cap, and bell stages, ultimately forming enamel, dentin, and periodontal structures. This developmental cascade ensures structural integrity and functional integration of the dentition within the craniofacial system. From an evolutionary perspective, human dentition is thecodont, heterodont, and diphyodont. Teeth are anchored in alveolar sockets, exhibit morphological specialization, and undergo only a single natural cycle of replacement. Consequently, once permanent teeth are lost, no endogenous mechanism exists for regeneration, underscoring the clinical importance of restorative and regenerative strategies.
Tooth loss arises from diverse etiologies, including developmental anomalies, dental caries, periodontal disease, and traumatic injury [1ā3]. Regardless of the cause, tooth loss disrupts oral homeostasis and exerts far-reaching functional, aesthetic, and psychological consequences. Epidemiological studies confirm its widespread prevalence, with a global pooled estimate of edentulism reaching approximately 22%, and as high as 32% in economically disadvantaged regions [4, 5]. In elderly populations, tooth loss is directly associated with frailty, impaired mastication, and malnutrition, contributing to systemic conditions such as sarcopenia and cardiovascular disease.
Loading authentic research manuscript (Pages 1ā5)...
Zhaorui Jin, Bo Yang, Siyuan Zhang, Zhi Liu, Yuhao Wang, An Lin, Kexin Yang, Mei Yu, Weidong Tian, Fangjun Huo (2026). Stem cell-driven biomedical technologies for tooth regeneration: engineering scaffolds, organoid models, and molecular targeted strategies. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-026-05044-y
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What are the main stem cell types used in tooth regeneration?
The review discusses dental stem cells such as DPSCs, SCAPs, PDLSCs, SHED, and iPSC-derived lineages, which are combined with bioactive scaffolds to promote odontogenic differentiation and periodontal attachment.
How do tooth organoids contribute to regenerative dentistry?
Tooth organoids recapitulate epithelial-mesenchymal interactions and enable controlled reconstruction of dentin-pulp and periodontal compartments, providing models for human odontogenesis and potential for bioengineered tooth germs.
What molecular pathways are targeted for tooth regeneration?
Key pathways include Wnt, BMP, FGF, TGF-β, and USAG-1, which are modulated to stimulate endogenous tooth regeneration and correct developmental defects.
What are the major challenges in stem cell-based tooth regeneration?
Challenges include stable neurovascular integration, optimization of stem cell-material crosstalk, precise control of spatiotemporal signaling, and long-term functional stability in vivo.
What future directions are proposed for clinical translation?
Future directions involve smart biomaterials, gene- and protein-based molecular targeting, organoid-guided regeneration, and iPSC-enabled personalized therapies to accelerate clinical translation.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.